PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
203.49%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
185.87%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
185.87%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
-0.66%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-29.56%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-185.91%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
-92.79%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
-92.79%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-3998.91%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-95.29%
Share count reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.
-95.29%
Diluted share reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.